Celsion Corp
Change company Symbol lookup
Select an option...
CLSN Celsion Corp
PSA-M Public Storage
BDX Becton Dickinson and Co
GGN GAMCO Global Gold, Natural Resources & Income Trust
GUT Gabelli Utility Trust
CHD Church & Dwight Co Inc
CHY Calamos Convertible & High Income Fund
CHW Calamos Global Dynamic Income Fund
CCVIX Calamos Convertible Fund Class A
ETY Eaton Vance Tax-Managed Diversified Equity Income Fund
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Closing Price
$2.06
Day's Change
-0.14 (-6.36%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.20
Day's Low
1.98
Volume
(Light)
Volume:
6,712,857

10-day average volume:
49,382,278
6,712,857

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, February 26, 2021
Celsion Corporation to Participate in the Virtual 33ʳ� Annual Roth Conference

Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings with investors during the Virtual 33...(Globe Newswire)

February 25, 2021
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores

Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or approximately one-third of the total, have been enrolled...(Globe Newswire)

February 23, 2021
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program

Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years Celsion Corporation (NASDAQ: CLSN), a clinical stage development company focused on DNA based immunotherapy and next generation vaccines, today...(Globe Newswire)

February 22, 2021
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer

Celsion's Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases Granted an Accelerated Development Pathway Designation Provides Potential for an Expedited Regulatory Review. (Globe Newswire)

Thinking about buying stock in Celsion Corp, Can Fite Biopharma, ConforMIS Inc, Citius Pharmaceuticals, or Vuzix Corp?

InvestorsObserver issues critical PriceWatch Alerts for CLSN, CANF, CFMS, CTXR, and VUZI. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

February 12, 2021
Celsion Corporation Announces Formation of Vaccine Advisory Board

Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the formation of a...(Globe Newswire)

February 11, 2021
Celsion Corporation Issues Letter to Stockholders

Discusses Broad-based DNA Vaccine Initiative, OVATION 2 Study, and Phase III OPTIMA Study Conclusions Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael H. Tardugno, the company's chairman...(Globe Newswire)

January 28, 2021
Celsion Corporation Files Provisional U.S. Patent Application for a Broad Range of Next Generation DNA Vaccines

The PLACCINE Platform Technology is Conceived to Enable Rapid Development of Vaccines That Can Address a Broad Range of Infectious Agents, including SARS-Associated Coronavirus (SARS-CoV) Patent Filing Claims a Novel Composition of Multiple...(Globe Newswire)

January 26, 2021
CELSION CORPORATION ANNOUNCES CLOSING OF $35 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase price of $1.35 per share, priced...(Globe Newswire)

January 22, 2021
Thinking about buying stock in AMC Entertainment, AzurRx BioPharma, Celsion Corp, Transocean, or Biolase?

InvestorsObserver issues critical PriceWatch Alerts for AMC, AZRX, CLSN, RIG, and BIOL. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

Celsion Corporation (NASDAQ: CLSN) ("Celsion" or the "Company"), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 25,925,925 shares of its common stock at a purchase price of $1.35...(Globe Newswire)

January 21, 2021
Thinking about buying stock in Celsion Corp, Jaguar Health, Precision BioSciences, electroCore, or Lipocine?

InvestorsObserver issues critical PriceWatch Alerts for CLSN, JAGX, DTIL, ECOR, and LPCN. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

December 29, 2020
FINAL CLSN DEADLINE TODAY: ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important Tuesday Deadline in Securities Class Action - CLSN

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the "Class Period"), of the important December 29, 2020 lead...(Globe Newswire)

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Celsion Corporation and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Celsion Corporation ("Celsion" or "the Company") (NASDAQ: CLSN) for violations of the securities laws. (BusinessWire)

December 28, 2020
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Celsion Corporation ("Celsion" or "the Company") (NASDAQ: CLSN) for violations of 10(b) and 20(a) of the Securities Exchange...(PR Newswire)

CLSN Final Deadline Tomorrow: Rosen, Top Ranked National Investor Attorneys, Reminds Celsion Corporation Investors of Important December 29 Deadline in Securities Class Action - CLSN

New York, New York--(Newsfile Corp. - December 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the...(Newsfile)

December 26, 2020
DEC. 29 DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Celsion Corporation - CLSN

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the "Class Period"). (Globe Newswire)

December 24, 2020
ROSEN, A TOP RANKED FIRM, Reminds Celsion Corporation Investors of Important Tuesday Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - CLSN

New York, New York--(Newsfile Corp. - December 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the...(Newsfile)

CELSION DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Celsion Corporation - CLSN

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from November 2, 2015 through July 10, 2020, inclusive (the "Class Period"). The lawsuit seeks...(Globe Newswire)

December 22, 2020
ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important December 29 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - CLSN

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the "Class Period"), of the important December 29, 2020 lead...(PR Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.